



IMDRF International Medical
Device Regulators Forum

PROPOSED DOCUMENT

International Medical Device Regulators Forum

Title: Optimizing Standards for Regulatory Use

Authoring Group: IMDRF Standards Working Group

Date: 26 March 2018

1
2
3
4
5
6
7
8

9
10
11
12
13

14

15
16
17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32 **Table of Contents**

33 1.0 Introduction..... 4
34 2.0 Scope 5
35 3.0 References..... 7
36 4.0 Definitions 7
37 5.0 General Principles 9
38 6.0 Recommendations for Standards Development 11
39 7.0 Enhancing Stakeholder Participation in Standards Development 16
40 8.0 IMDRF and Standards Development..... 19
41 Appendices..... **Error! Bookmark not defined.**
42 Appendix A: Problems in Standards for Regulatory Purposes **Error! Bookmark not defined.**
43 Appendix B: How to Contact a National Body/Committee of a Country .. **Error! Bookmark not defined.**
44

45 **Preface**

46

47 The document herein was produced by the International Medical Device Regulators Forum
48 (IMDRF), a voluntary group of medical device regulators from around the world. The document
49 has been subject to consultation throughout its development.

50

51 There are no restrictions on the reproduction, distribution or use of this document; however,
52 incorporation of this document, in part or in whole, into any other document, or its translation
53 into languages other than English, does not convey or represent an endorsement of any kind by
54 the International Medical Device Regulators Forum.

55

56

57 **1.0 Introduction**

58 **1.1 Background**

59 Standards play a significant role in the design, manufacture and regulation of medical devices.
60 Important tools for conformance assessment, standards facilitate and support innovation and help
61 ensure that devices are safe and perform as expected. As medical devices grow in complexity and
62 international markets expand, standards offer a means to streamline and harmonize regulatory
63 processes around the world.

64
65 Moreover, standards tend to be used and cited by many sectors and organizations across
66 economic systems, from product developers to associations, testing facilities and governments.
67 Standards are especially valuable as they ‘... generally reflect the best experience of industry,
68 researchers, consumers and regulators worldwide, and cover common needs in a variety of
69 countries.’¹

70
71 As standards have grown in prominence in recent decades, evidence of their utility compels
72 industry, Regulatory Authorities (RAs), clinicians and public health experts to dedicate resources
73 to the development and promulgation of standards. However, standards are frequently written in
74 ways that diminish their utility in regulatory processes. For example, some standards do not
75 sufficiently contemplate conformity assessment testing needs. Other standards are too flexible or
76 unclear in expectations, or do not meet a specific need, either for the market or regulators. These
77 and other shortcomings highlight the importance of considering how medical devices are
78 regulated when building a standard, so that a firm’s declaration of conformance with it will
79 inspire reviewers’ confidence and streamline the approval process. See Annex A for more
80 information.

81
82 In preparing this guidance, IMDRF learned that while all its member regions use standards for
83 regulatory purposes, they differ in how they apply and/or recognize them. In addition, IMDRF
84 found that active participation in the standards development processes of the International
85 Organization for Standardization (ISO), the International Electrotechnical Commission (IEC)
86 and their corresponding national/mirror committees across RAs is uneven, and resource
87 constraints, particularly time and people, hinder RA representation.

88
89 IMDRF’s conclusions – that standards can be improved by increasing and enhancing RA
90 participation in standards developing processes and through better cooperation and coordination
91 within the IMDRF network – led to the creation of this guidance. It offers clear recommendations
92 to RAs, Standards Developing Organizations (SDOs) and other stakeholders for improving
93 standards for use in medical device regulatory activities.

94 **1.2 Role of Standards in Regulatory Processes**

95 Although regulatory processes among IMDRF regions differ, RAs share the common objectives
96 to ensure medical device safety and performance and to protect public health. International
97 consensus standards are based upon science, technology and experience and generally reflect the

¹<http://www.iec.ch/about/activities/standards.htm?ref=home>

98 best experience of industry, researchers, consumers, regulators and other experts
99 worldwide. IMDRF members affirm their collective belief that reliance upon consensus standards
100 is a key element of a robust regulatory framework that will promote efficiencies and innovation
101 while facilitating an appropriate assessment of device safety and performance.

102
103 Consensus standards contribute to regulatory quality because consensus-based SDOs must
104 demonstrate adherence to ‘transparency, openness, impartiality, effectiveness and relevance,
105 coherence, due process and technical assistance,’ among other principles.² The rigor conferred
106 by the consensus process ensures that many interests are considered and that no single party
107 wields disproportionate influence. Note: In this guidance, we refer to ‘standards’ without
108 additional modifiers indicating if it is a consensus or international consensus standard. IMDRF
109 believes that globally accepted consensus standards are preferred; however, regional, national
110 and consortia standards may be equally useful, especially in emerging technologies in which
111 these SDOs may be able to react quickly to changes in the state of the art.

112 1.3 Benefits of Optimizing Standards for Regulatory Use

113 Standards offer important technical tools to assess medical devices. Good standards can
114 streamline the device review process, improve the efficiency of regulations and establish
115 productive dialogue among RAs, manufacturers, clinicians and the public.

116
117 With the greater use of commonly accepted standards among regulators comes harmonization,
118 which supports IMDRF’s mission: ‘...to strategically accelerate international medical device
119 regulatory convergence to promote an efficient and effective regulatory model for medical
120 devices that is responsive to emerging challenges in the sector while protecting and maximizing
121 public health and safety.’³

122
123 IMDRF believes that RAs’ adoption of the recommendations in this guidance will lead to
124 advances in global regulatory harmonization. For manufacturers, harmonization will help speed
125 products to market, and promote international trade and market integration. Patients will benefit
126 from improved access to life-saving and life-enhancing treatments and SDOs will enjoy greater
127 success as standards grow in relevance and utilization.

128 2.0 Scope

129 This IMDRF guidance serves as an educational tool and resource for regulators, SDOs and other
130 stakeholders involved in standards writing to ensure that standards are useful for the regulatory
131 oversight of medical devices. It suggests improvements in the standards writing process
132 and recommends best practices for effective RA participation in standards development that will
133 advance their use for regulatory purposes and ultimately promote the harmonization of
134 regulatory schemes globally. While we refer specifically to ISO and IEC in this document, most
135 consensus-based SDOs follow similar procedures and rules, though terminologies may differ.

²https://share.ansi.org/shared%20documents/Standards%20Activities/NSSC/USSS_Third_edition/ANSI_USSS_201.pdf and
ISO/IEC Guide 2:2004 Standardization and related activities – General vocabulary accessed at
<https://www.iso.org/standard/39976.html>

³IMDRF Strategic Plan 2010, accessed at <http://imdrf.org/docs/imdrf/final/procedural/imdrf-proc-151002-strategic-plan-2020.pdf>

136 *Note:*

137 This document does not establish competency or training requirements for experts/liaisons
138 appointed to standards development activities nor does it offer direction on how regulators
139 should implement the use of standards, though it is anticipated that RAs' use of standards will be
140 enhanced when standards are written with greater attention to regulatory utility. This guidance
141 applies to all medical devices, including *in vitro* diagnostic devices.

142 3.0 References

- 143 3.1 IMDRF Essential Principles of Safety and Performance of Medical Devices and IVD
144 Medical Devices: 2018 (IMDRF GRRP WG(PD1)/N47 forthcoming)
- 145 3.2 ISO Conformity Assessment tools to support public policy
146 https://www.iso.org/sites/cascoregulators/02_casco_toolbox.html
- 147 3.3 ISO/IEC Directives Parts 1 (Ed. 13, 2017) and 2 (Ed. 7, 2016)
- 148 3.4 ISO/IEC Guide 59, Code of good practice for standardization 1994
- 149 3.5 ISO/IEC 17007:2009, Conformity assessment – Guidance for drafting normative
150 documents suitable for use for conformity assessment
- 151 3.6 ISO/IEC 17050-1:2004 Conformity Assessment – Supplier’s Declaration of Conformity –
152 Part 1: General Requirements
- 153 3.7 ISO/IEC 17050-2:2004 Conformity Assessment – Supplier’s Declaration of Conformity –
154 Part 2: Supplemental Information
- 155 3.8 ISO 14971:2007 Medical devices – Application of risk management to medical devices
- 156 3.9 World Health Organization WHO Global Model Regulatory Framework for Medical
157 Devices including in vitro diagnostic medical devices 2017
- 158 3.10 World Trade Organization Agreement on Technical Barriers to Trade 1994

159 4.0 Definitions

- 160 4.1 **Consensus Standards:** ‘are standards developed through the cooperation of all parties
161 who have an interested in participating in the development and/or use of the standard.
162 Consensus requires that all views and objections be considered, and that an effort be made
163 toward their resolution. Consensus implies more than the concept of a simple majority but
164 not necessarily unanimity.’ (The Society for Standards Professionals: [http://www.ses-
165 standards.org/?58](http://www.ses-standards.org/?58))
- 166 4.2 **Essential Principles/Essential Principles of safety and performance:** fundamental high-
167 level requirements that when complied with ensure a medical device is safe and performs
168 as intended (ISO 16142-2:2017)
- 169 4.3 **Manufacturer:** “Manufacturer” means any natural or legal person⁴ with responsibility for
170 design and/or manufacture of a medical device with the intention of making the medical
171 device available for use, under his name; whether or not such a medical device is designed

⁴The term “person” that appears here and in the other definitions of this document, includes legal entities such as a corporation, a partnership or an association.

172 and/or manufactured by that person himself or on his behalf by another person(s).
173 (GHTF/SG1/N055:2009)

174 4.4 **Medical Device:** Any instrument, apparatus, implement, machine, appliance, implant,
175 reagent for in vitro use, software, material or other similar or related article, intended by the
176 manufacturer to be used, alone or in combination, for human beings, for one or more of the
177 specific medical purpose(s) of:

- 178 • diagnosis, prevention, monitoring, treatment or alleviation of disease,
- 179 • diagnosis, monitoring, treatment, alleviation of, or compensation for, an injury,
- 180 • investigation, replacement, modification, or support of the anatomy, or of a physiological
181 process,
- 182 • supporting or sustaining life,
- 183 • control of conception,
- 184 • disinfection of medical devices,
- 185 • providing information by means of in vitro examination of specimens derived from the
186 human body; and does not achieve its primary intended action by pharmaco-
187 logical, immunological, or metabolic means, in or on the human body, but which may be
188 assisted in its intended function by such means.

189 Note 1: Products which may be considered to be medical devices in some jurisdictions but
190 not in others include:

- 192 • disinfection substances,
- 193 • aids for persons with disabilities,
- 194 • devices incorporating animal and/or human tissues,
- 195 • devices for in-vitro fertilization or assisted reproduction technologies.

196 (GHTF/SG1/N071:2012)

197 Note 2: For clarification purposes, in certain regulatory jurisdictions, devices for
198 cosmetic/aesthetic purposes are also considered medical devices.
199

200 4.5 **Performance:** The ability of a medical device to achieve its intended purpose as stated by
 201 the manufacturer. Performance may include both clinical and technical aspects. (IMDRF
 202 GRRP WG(PD1)/N47 forthcoming)

203 4.6 **Recognized Standards:** Standards deemed to offer the presumption of conformity to
 204 specific essential principles of safety and performance. (GHTF/SG1/N78:2012)

205 4.7 **Regulatory Authority (RA):** A government body or other entity that exercises a legal
 206 right to control the use or sale of medical devices within its jurisdiction, and that may
 207 takenforcement action to ensure that medical products marketed within its jurisdiction
 208 comply with legal requirements. (GHTF/SG1/N078:2012)

209 4.8 **State of the Art:** Developed stage of technical capability at a given time as regards
 210 products, processes and services, based on the relevant consolidated findings of science,
 211 technology and experience. (ISO/IEC Guide 2:2004)

212 5.0 General Principles

213 Standards help facilitate the assessment of the safety and performance of medical devices. They
 214 represent the consensus of a variety of experts and interested entities, and a commitment to their
 215 use presents an opportunity to promote the global harmonization of regulatory processes. RAs
 216 and all interested stakeholders should support and contribute to standards development to
 217 encourage the publication of standards that are useful in the regulation of medical devices and
 218 can streamline review processes. Outlined below are three key expectations for the development
 219 and promulgation of regulatory-ready standards: a commitment to IMDRF's *Essential Principles*
 220 *of Safety and Performance of Medical Devices and IVD Medical Devices*, an emphasis on
 221 performance over design stipulations in writing standards, and the importance of a consensus
 222 approach.

223 5.1 **IMDRF Essential Principles of Safety and Performance of Medical Devices and IVD** 224 **Medical Devices (IMDRF EPs)**

225 IMDRF's *Essential Principles* identify the high-level criteria that, when met, indicate that a
 226 medical device is safe and performs as expected. Standards that are written with regulatory needs
 227 in mind will address one or more of the IMDRF EPs, and should reflect:

- 228 • a close relationship of the scope of the standard to one or more of the IMDRF EPs,
- 229 • the clarity and completeness of the requirements contained in the standard as it relates to
 230 a specific EP,
- 231 • the existence of test methods for determining compliance with each of the requirements
 232 in the standard, and the definition of clear acceptance criteria for determining that each
 233 technical requirement is met.

234

235 5.2 Performance versus Design Stipulations

236 There is broad agreement among SDOs and others that it is much preferred to express a
 237 standard's requirements with references to performance, rather than to specific device features.
 238 As noted in the ISO/IEC Directives Part 2, this approach fosters innovation and healthy
 239 marketplace dynamics.

240 An example from the Directives illustrates this principle:

241 *'Different approaches are possible in the specification of requirements concerning a*
 242 *table:*

243 *Design requirements: The table shall have four wooden legs.*

244 *Performance requirements: The table shall be constructed such that [the table top*
 245 *remains level and at its original height] when subjected to ... [stability and strength*
 246 *criteria].'⁵*

247 5.3 Consensus Approach

248 IMDRF believes that for regulatory purposes international, regional, national, consortia and
 249 industry standards should be developed by organizations using consensus principles. Standards
 250 should also demonstrate the following characteristics:

- 251
- 252 • Fairness: the needs of all stakeholders, including regulators, are considered in standards
- 253 development.
- 254 • Compatibility: standards are compatible with the internationally accepted principles of
- 255 safety and performance of medical devices.
- 256 • State of the art: standards represent the state of art in a technological field.
- 257 • Efficiency: they should also promote economic benefits, e.g., reducing redundant
- 258 reporting requirements, streamlining regulatory activities and harmonizing expectations
- 259 across different countries and regions.
- 260 • Completeness: within its scope, a standard address all predictable elements related to
- 261 Essential Principles of device safety and/or performance.
- 262 • Verifiability: requirements include verifiable objective measurements.
- 263 • Repeatability: testing methods in standards will yield consistent results across different
- 264 certified test houses.
- 265 • Consistency: terms and symbols across standards are as consistent as possible.
- 266 • Clarity: standards are clear, unambiguous, and easily understood.
- 267 • Accessibility: standards and associated documents should be reasonably available to
- 268 relevant stakeholders.
- 269

270 The remaining sections of this guidance outline recommendations for standards development and
 271 participation that are based upon these general principles, and which will foster the development
 272 of standards that are optimized for regulatory use.

⁵See ISO/IEC Directives Part 2, accessed at http://www.iec.ch/members_experts/refdocs/iec/isoiecdir-2%7Bed7.0%7Den.pdf

273 6.0 Recommendations for Standards Development

274 This section offers specific suggestions for improving standards for regulatory use and for
275 achieving harmonization.

276 6.1 Optimizing Standards Content

277 Standards should be crafted in such a way that conformity to them can reduce the burden of
278 regulatory review and demonstrate conformance to IMDRF's EPs. To achieve this, standards'
279 content must contain objective and specific requirements that clearly indicate how conformance
280 can be achieved and conveyed. Adherence to the following will improve standards' content and
281 suitability for regulatory purposes:
282

- 283 • Standards should include a rationale explaining the general requirements in the
284 standard that may assist in interpreting the meaning and/or purpose of the standard.
285 The rationale should identify test methods and/or other means of demonstrating
286 compliance. In addition, the rationale should demonstrate how conformance to the
287 standard achieves its goal of satisfying the associated EPs.
288
- 289 • To better indicate the breadth of experts involved within the development activity,
290 standards should provide a summary of the type of stakeholder groups involved in the
291 drafting and editing of the standard. This should apply to both SDOs and national-
292 level mirror committee activities.
293
- 294 • When a reasonably foreseeable risk, hazard or a hazardous situation is identified
295 without a specific requirement for its mitigation, the standard should clearly identify
296 this hazard and provide direction on how to address the residual risk as appropriate
297 (e.g., conduct a Risk Analysis).
298
- 299 • The standard's scope should be clear in terms of how it achieves the EPs of safety and
300 performance addressed in the standard.
301
- 302 • Standards should include terms and definitions that have been established and
303 accepted in other standards (see *ISO/IEC Directives Part 2*).
304
- 305 • If the scope of a standard includes clinical performance as part of the normative
306 requirements, the standard should include acceptance criteria required to demonstrate
307 compliance with the standard. Where these criteria cannot be adequately established,
308 but are still addressed in the standard, it should indicate that additional clinical
309 evaluation may be required.
310
- 311 • When possible, standards should contain clear and quantitative acceptance criteria
312 that can adequately support IMDRF EPs.
313
- 314 • Where provisions permit not meeting an acceptance criterion or a requirement while
315 still allowing a claim of conformance, justification should be provided as to why the

316 acceptance criteria are not mandatory and how to demonstrate conformance to the
 317 standard (see *ISO/IEC 17050-2:2004 – Supplier’s Declaration of Conformity - Part 2*
 318 *Supplemental Information*).

- 319
- 320 • Where a requirement is included without specific acceptance criteria, it should be
 321 clearly identified as to how conformance can be met.
 322
- 323 • Whenever alternative solutions are offered in a document and preferences for
 324 different alternatives provided, the reasons for the preferences should be explained in
 325 the introduction to the standard (see *ISO/IEC Directives Part 2:2016* for more
 326 information).
 327
- 328 • Acceptance criteria should be validated as relevant for meeting safety and
 329 performance requirements and a rationale supporting the validation methods should
 330 be included.
 331
- 332 • Test methods should be verified as reliable to ensure that tests can be successfully
 333 conducted and consistent results obtained. When technical requirements are stipulated,
 334 associated test methods should use well accepted approaches. New or unfamiliar test
 335 methods should likewise be verified as reliable.
 336
- 337 • When a standard is undergoing revision, it should highlight the changes from the
 338 previous version (e.g., show a red-line version of the standard).
 339
- 340 • Standards should contain, as an annex, a table that cross references, or maps, the
 341 standard’s clauses to the Essential Principles.

342 6.2 Best Practices for Standard Development Procedures

343 Standards should be developed using consensus principles and support the values articulated by
 344 the World Trade Organization, the World Health Organization and others: accessibility,
 345 transparency, broad representation and consideration of interests in consultations.⁶ Applying
 346 consensus requirements to standards confers credibility to the future published standard and
 347 enhances the probability of its adoption and promulgation.
 348

349 At every stage of the standards development process, careful thought should be given to how a
 350 standard can be used by RAs. In the preliminary and proposal stages, the effect on regulatory
 351 practices and industry should be evaluated. The justification for the need for the standard should
 352 clearly identify the purpose in its scope and specify how it will achieve that purpose (e.g.,
 353 meeting an EP, addressing new technologies, or mitigating a public health concern or a known
 354 deficiency from post market reports).

⁶See Annex 3 of the World Trade Organization’s *Agreement on Technical Barriers to Trade*, accessed at https://www.wto.org/english/docs_e/legal_e/17-tbt_e.htm and the World Health Organization’s *Medical Device Regulations: Global Overview and Guiding Principles*, accessed at http://www.who.int/medical_devices/publications/en/MD_Regulations.pdf

355
356 When crafting the business plan, standards developers should carefully and comprehensively
357 study objective market, regulatory and/or safety needs. A robust analysis of need during the
358 business plan stage will preclude the drafting of standards that are unnecessary, duplicative, or of
359 little regulatory use. In addition, before drafting begins, standards writers should investigate
360 whether existing standards already address the issue under consideration. Avoiding duplication
361 of and conflicts between existing standards and new proposals – at national, regional and
362 international SDO levels - will save time and resources.

363
364 Once drafting is underway, working groups solicit and deliberate stakeholders' comments to the
365 draft standard. At this stage, the RA comments both from national committees/bodies or from
366 IMDRF can be particularly helpful, as they offer insights into the global regulatory usefulness of
367 the standard. In the enquiry stage, it is also useful to include additional comment information on
368 the comment form. In addition to general, technical and editorial categories, the form should also
369 include two additional comment categories: regulatory and clinical. The awareness of a
370 comment's regulatory or clinical origins will add valuable perspective to the standards
371 developing process.

372
373 Because some standards address not only performance but also broader public health issues,
374 IMDRF encourages SDOs to make information about these standards used for regulatory
375 purposes more accessible throughout the development process, thereby assuring adequate input
376 from the larger medical and public health communities, including RAs.

377
378 SDO committees should strengthen tracking and evaluation on the post-market performance of
379 the applicable technology from the published standard. SDOs should also encourage the
380 application of a rapid-response procedure to revise standards when issues related to product
381 safety arise.

382
383 Finally, in order to deepen awareness of and expertise in the regulatory fitness of standards and
384 to encourage participation in their work, SDOs should regularly organize and offer training on
385 standards and standards development procedures to all interested entities. Equally importantly,
386 SDOs should actively collaborate with IMDRF to train the technical committees and working
387 groups on regulatory requirements of medical devices, and to encourage member countries to
388 carry out similar training in their own agencies.

389

390 **6.3 Use of Standards in Meeting IMDRF *Essential Principles***


391 Standards that contain detailed requirements may be used to demonstrate conformance with
392 some or all of the IMDRF EPs. These principles provide a framework for regulatory expectations
393 and represent a consensus on fundamental design and manufacturing requirements that, when
394 met, indicate that a medical device is safe and performs as intended. Essential Principles of
395 safety and performance provide broad, high-level, criteria for design, production, and
396 postproduction (including post-market surveillance) throughout the life-cycle of all medical
397 devices.

398

399 Standards that conform to the relevant EPs provide a greater level of detail and specificity than
400 can be expressed in the EPs. Thus, when writing standards it is helpful to test the standard
401 against the relevant EP(s). Mapping a standard to its EP will serve to ensure that standards
402 developers are giving adequate consideration to the regulatory ramifications of the standard and
403 its applications, and ultimately build confidence among RAs that a standard is fit for use in
404 conformity assessment. This approach has the added benefit of promoting harmonization among
405 jurisdictions. Note: the use of specific standards depends on the requirements of the RAs having
406 jurisdiction. In addition, some RAs may have additional requirements outside these EPs.

407
408 Figure 1 below uses examples to delineate how standards, when aligned with the relevant EPs,
409 contribute to the assessment of a device's performance. The first example is for technical
410 performance and the second is for clinical performance.

411



412
413
414

Figure 1: Example of standards addressing Safety and Performance of the IMDRF *Essential Principles*

415

416 **7.0 Enhancing Stakeholder Participation in Standards Development**

417 Standards' role in international commerce and their impact on competitiveness and other
418 priorities confer a special significance to contributions from RAs. RAs' engagement promotes
419 the development of standards that facilitate and shape innovation in ways that benefit global
420 public health, as well as the medical device marketplace. When actively contributing to standards
421 development, RAs interact with a wide range of stakeholders at the domestic and international
422 levels and contribute substantively to technical and policy solutions with industry experts,
423 international counterparts, other regulators and policymakers, and public health organizations.
424

425 RAs' engagement is enhanced by organizational support from their respective agencies. IMDRF
426 recommends that, for those who use standards for regulatory, procurement, or other mission
427 related activities, a formal standards function be established, e.g., appointment of a designated
428 standards executive and/or a department responsible for the RA's standards activities.

429 **7.1 International, regional and national level participation: joining the conversation**

430 Standards development takes place at the international, regional and national levels.
431 Internationally, consensus SDOs draft, publish and sell standards in the global market. While
432 some SDOs establish membership and participation by individual experts (e.g., ASTM
433 International), membership in IEC and ISO committees (including technical committees,
434 subcommittees, working groups and maintenance teams) is by country only. 'Participating'
435 member countries send a limited, prescribed number of delegates to meetings around the world
436 in which standards are written, reviewed, revised or rescinded. They also conduct other
437 committee tasks such as writing guidance, technical reports and business plans. This work is
438 formal and governed by strict protocols and rules designed to ensure that consensus status is
439 maintained.
440

441 Countries, as the members of ISO and IEC, work on a national level to formulate their positions
442 on the various SDO priorities. ISO and IEC member countries designate an organization to act as
443 'Member Body' (in ISO terminology) or "National Committee" (in IEC terminology); per the
444 ISO/IEC Directives Part 1, this document will use the term 'national body' to refer to them. The
445 national body is responsible for relevant activities of ISO and IEC within their respective
446 countries, including audits and registration of international experts to participate in IEC/ISO
447 working group, review of new standard proposals, guidance and supervision of commenting and
448 voting, and hosting ISO and IEC conferences.
449

450 The national body manages various national or mirror committees (called Technical Advisory
451 Groups, or TAGs in the US; this document will hereafter use the term 'mirror committees')
452 whose work parallels that of ISO and IEC committees and working groups at the international
453 level. Individuals in these groups also constitute the pool of nominees from which the national
454 body draws for official delegates to the ISO and IEC meetings.
455

456 The objectives of these national-level mirror committees are to develop consensus on the many
457 issues about which ISO and IEC will write standards and reports, and their decisions will form
458 the basis of their countries' official positions. These groups are ordinarily accredited by the
459 national bodies; mirror committees also surveil the environment for needs and opportunities that
460 the SDO should consider, and propose new work items to address those needs.
461

462 To increase utilization of standards for regulatory applications, RAs should participate in
463 standards development at both the national and international levels. At the international level,
464 RA engagement is welcomed in the various committees within IEC and ISO and regulators are
465 strongly encouraged to serve as experts through their official country delegations.
466

467 Equally important is participation in the mirror committees. As noted above, the national bodies
468 develop consensus on their countries' positions and votes; their nominating function to ISO and
469 IEC delegations makes national level engagement even more important for RAs. This
470 accessibility at the national level supports consensus principles and is an important feature that
471 facilitates participation in standards development without requiring the membership and
472 resources necessary for ISO and IEC membership.
473

474 Joining the ISO and IEC national bodies and mirror committees is a key first step for RAs. It is
475 not always clear how one joins a mirror committee. Most countries' national bodies encourage
476 participation and direct their mirror committees to offer membership to all interested
477 stakeholders, though they may be administered by private organizations who may charge dues or
478 membership fees. RAs often have membership status through their agency or government and
479 that membership may entitle them to join mirror committees. Understanding and identifying
480 relevant committees may require investigation; [Annex B](#) offers specific steps for identifying
481 committees of interest and you should not hesitate to contact the many individuals listed on the
482 SDOs' websites for clarification.

483 7.2 **Recommendations for participation: submitting effective comments**

484 Standards are written according to an established and orderly procedure, from the proposal stage
485 through draft iterations and finally a vote and publication. RAs should enter the process as early
486 in the standard's life cycle as possible. If regulators contribute expertise early, particularly at the
487 New Work Item Proposal (NWIP) stage, the opportunity to shape its direction and enhance
488 regulatory utility is maximized. Figure 2 below depicts the stages in the standards development
489 process over time, from left to right. The further along the standard moves in the process, the less
490 opportunity there is for substantive changes.
491




Figure 2: Stages of ISO standards development

492
493
494
495
496
497
498
499
500
501

On their Web sites, ISO and IEC publish comprehensive information about where each standard currently resides in the development process. Interested stakeholders may search by the Technical Committee or Sub-Committee working on a standard or the standard itself; the stages are coded for easy identification (see https://www.iso.org/files/live/sites/isoorg/files/developing_standards/docs/en/stage_codes.pdf) and http://www.iec.ch/standardsdev/resources/processes/stage_codes.htm).

502
503
504
505
506
507
508
509

Once engaged, it is incumbent upon participants to have a clear understanding of the standard's substance and purpose, to pay attention to others' thoughts and to carefully analyze any challenges or problems that the draft document presents. They should solicit input from their regulatory colleagues (both in their own country and among their peers, as well as other experts who may be interested in the topic), and give consideration to implications that elements of the standard will have on the regulatory activities, such as the review processes for conformity assessment, testing methods and audit requirements.

510
511
512
513
514
515
516

The next step is to articulate one's position clearly and timely and in the format specified by the national body. Protocols for submitting comments are clear and straightforward; they encourage not only an explanation of the commenter's suggested improvements, but also the submission of specific language that can replace text that one disagrees with. Effective comments are clear, concise and germane to the issue. For more information on how to provide effective comments, please see the ISO/IEC Directives Part 2 (http://www.iec.ch/members_experts/refdocs/iec/isoiecdir-2%7Bed7.0%7Den.pdf).

517
518
519
520
521

RAs should take advantage of every opportunity to submit comments. The entire standards development system is predicated upon stakeholder input and having RAs' insights during the entire process means that regulatory use will be considered in time for it to make a difference.

522 RAs should not only join but should also seek leadership positions within SDO committees and
523 national bodies. Serving in a leadership role is important for several reasons. First, having
524 regulators in leadership positions will result in more useful standards for regulatory
525 purposes. Second, those who hold an office will be able to contribute substantively to the overall
526 good of the standards development process. Finally, it will benefit both the participant and his
527 organization professionally.

528 **8.0 IMDRF and Standards Development**

529 Representing medical device regulatory authorities from several major jurisdictions, IMDRF
530 enjoys a unique position and authority in the international community. As such, it capitalizes on
531 its collective expertise and relationships with SDOs that advance our shared goal of expanding
532 the use of standards to streamline regulatory requirements. While IMDRF engagement with
533 SDOs in no way diminishes the importance of regulators' participation (e.g., in both their
534 national bodies and at the international SDO levels), agreements to collaborate with ISO and IEC
535 provide mutual benefit to IMDRF, SDOs, and RAs. The more these entities interact, the greater
536 the impact regulators will have on the standards development process.

537 In its role as partner to the SDOs and advocate for member RAs, IMDRF acts as a resource to
538 both, and serves as a hub for communicating needs and priorities in both directions: from the
539 SDOs to regulators and vice versa. In addition to facilitating communications, IMDRF offers
540 oversight and assistance to RAs in their contributions to standards development, particularly in
541 commenting support, both through their national bodies and through IMDRF.

542 For their part, through these interactions (including joint meetings and training sessions), SDOs
543 enhance RAs' confidence in their standards by committing to consensus principles, particularly
544 balanced participation in its working groups, transparency at all levels of the standards
545 development process, and the production of effective impact assessments that explicitly consider
546 regulatory applications in new work items. Additionally, SDOs' support for the IMDRF EPs and
547 other priorities such as risk management and quality management programs fosters regulatory-
548 ready standards and their ultimate adoption and promulgation.

549
550 This close cooperation further ensures that other advances in standards harmonization will be
551 possible, e.g., procedures to identify, correct and inform standards' users about possible
552 shortcomings that might lead to unsafe devices, increased transparency on the authorship of SDO
553 output and comments (regulator, clinician, industry, etc.), and evaluation of the implementation
554 of published standards.

555
556 IMDRF is the voice of its members, thereby advancing progress toward IMDRF's key strategic
557 goal of '...improving the suitability of standards for regulatory authorities and effective
558 regulatory authority involvement at each stage in standards development.'⁷
559

560

⁷ IMDRF Strategic Plan 2020, accessed at <http://imdrf.org/docs/imdrf/final/procedural/imdrf-proc-151002-strategic-plan-2020.pdf>

561

562

563

564

565

566

567

568

569

570

Appendices

571 **Appendix A: Problems in Standards for Regulatory Purposes**

572
 573 IMDRF identified key shortcomings in the way standards are currently written. Problems with
 574 representation, decision-making and processes, and a lack of understanding in ISO and IEC
 575 about what RAs need are all important issues. Discussions with ISO and IEC leadership lead us
 576 to conclude that, while challenging, these problems can be resolved with appropriate intervention
 577 and collaboration among RAs and SDOs.

578
 579 Note: it is acknowledged that various RAs may use standards differently. For some RAs,
 580 regulatory authorizations or approvals may be based entirely on compliance to consensus
 581 standards as a mandatory approach to obtaining authorization to market a medical device. For
 582 some RAs, standards may be an optional element that can be used to complement and augment
 583 other documentation, test reports, and objective evidence used to demonstrate safety and
 584 effectiveness. The approaches used by RAs might also differ based on the risk classification of
 585 the medical device.

586 **Representation and Expertise of Standards Committees**

- 587 • *Poor participation by RAs*, due to financial and human costs of engagement, precludes
 588 substance and language that are useful for regulatory purposes from appearing in final
 589 standards. If regulators are not present at the drafting and commenting stages at a
 590 minimum, the standards will not reflect requirements conducive to product review
 591 processes.
- 592
 593 • *A profusion of work items* (and duplication across SDOs) stresses resources. Most
 594 regulatory authorities characterize themselves as understaffed; those who work on
 595 standards often do so on an extra-curricular basis and must carefully prioritize those
 596 standards most important to their areas of expertise. Frequently, RAs are unable to
 597 contribute manpower to all pertinent standards.
- 598
 599 • *Unbalanced representation* in drafting and voting can result in some groups'
 600 disproportionate voice in and impact on standards development. The ramifications of a
 601 standards committee having, for example, an industry-heavy composition can be
 602 significant if clinical, public health and/or safety experts are under-represented.
- 603
 604 • *'Turf battles'* among TCs and SCs sometimes stymie progress. It is sometimes unclear
 605 which TCs and SCs should have jurisdiction in a technical area, which can slow progress
 606 as ownership is worked out.
- 607

608 **Transparent processes and decision-making**

- 609 • *Working document accessibility* is often unpredictable, making analysis, commenting and
 610 future promulgation difficult. When regulators have easy and reliable access to the drafts,
 611 they are more likely to contribute substantively on behalf of the review process.

612
613
614
615
616
617
618
619
620
621
622

623

624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652

- *Lack of transparency* on authorship of proposals, comments and positions hinder an understanding of other positions and their origins. Knowing which individual or stakeholder submitted specific input can help regulators understand and effectively balance the overall direction of the standard.
- *Adherence to deadlines* is often poor; business plans need to clearly specify due dates, and TCs should demonstrate better accountability to timelines, especially for emergent and urgent standards. Missing deadlines and extending work items make it even more difficult for RAs to be able to contribute where they are most needed.

Usefulness for regulatory purposes

- *Inadequate RA input* into design of key standards often leads to out-of-scope substantive content. ‘Scope creep’ for example can result in standards that do more than is needed, reducing their utility and adoption.
- *Insufficient attention is paid to evaluating need* in developing NWIPs. IMDRF members note that standards teams should spend more time determining a market, safety or regulatory need before the standard is actually drafted (this may be aided by developing a set of design specifications for regulatory purposes). This will prevent unnecessary standards from being developed, while redirecting participants to pursue a more appropriate outcome, e.g., a technical report or other option.
- *Impact assessments need outside review* to assure a standard is ‘fit for purpose.’ For example, gaining insights from testing laboratories will ensure that conformance assessment is doable and reasonable.
- *Mixed standards* can be difficult to use in product reviews. Standards that combine, for example, product and process requirements present challenges for recognition programs and for the review process.
- *Conformance* considerations (e.g., validation) and clarity of expectations need to be built into standards. Since conformance assessment, testing and declarations are among standards’ most important functions it is important to always keep these practical, applied aspects of standards in mind when developing them.
- *Content of standards can be too flexible.* Technological changes encourage the allowance of more flexibility to accommodate the rapid rate of advances. That flexibility can render standards less useful as they may not adequately identify minimum requirements for quality, safety and/or effectiveness/performance.

653 Appendix B: How to Contact a National Body/Committee of a Country

654 Source: Global Medical Technology Association

655

656 To effectively participate in standards developed by national voting (e.g., ISO/IEC), it is
657 important to know that your participation is authorized through your country's National
658 Body/Committee. This annex provides information on how to reach your National
659 Body/Committee.

660

661 For an IEC committee

662 Go to the IEC website link at this link: <http://www.iec.ch/dyn/www/f?p=103:6:0##ref=menu>

The screenshot shows the IEC website's 'List of IEC Technical Committees and Subcommittees' page. The page features a navigation menu with options like 'You & the IEC', 'About the IEC', 'News & views', 'Standards development', 'Conformity assessment', 'Members & experts', 'Developing countries', 'Webstore', and 'Advanced search'. The main content area displays a table of committees and subcommittees with columns for 'Committee', 'Title', 'Publications', 'Work Programme', and 'SBP'. The table lists several committees and subcommittees, including TC 62, SC 62A, SC 62B, SC 62C, and SC 62D.

Committee	Title	Publications	Work Programme	SBP
TC 62	Electrical equipment in medical practice	1	0	
SC 62A	Common aspects of electrical equipment used in medical practice	59	14	
SC 62B	Diagnostic imaging equipment	70	9	
SC 62C	Equipment for radiotherapy, nuclear medicine and radiation dosimetry	38	5	
SC 62D	Electromedical equipment	96	33	

663

664

665 Scroll down and click on the TC or SC you want

Committee	Title	Publications	Work Programme	SBP
TC 62	Electrical equipment in medical practice	1	0	
SC 62A	Common aspects of electrical equipment used in medical practice	59	14	
SC 62B	Diagnostic imaging equipment	70	9	
SC 62C	Equipment for radiotherapy, nuclear medicine and radiation dosimetry	38	5	
SC 62D	Electromedical equipment	96	33	

666

667

668 Click on the tab marked Structure

The screenshot shows the IEC website's 'SC 62A Dashboard' page. The page features a navigation menu with options like 'You & the IEC', 'About the IEC', 'News & views', 'Standards development', 'Conformity assessment', 'Members & experts', 'Developing countries', 'Webstore', and 'Advanced search'. The main content area displays a table of committees and subcommittees with columns for 'Committee', 'Title', 'Publications', 'Work Programme', and 'SBP'. The 'Structure' tab is highlighted in the navigation menu.

Committee	Title	Publications	Work Programme	SBP
TC 62	Electrical equipment in medical practice	1	0	
SC 62A	Common aspects of electrical equipment used in medical practice	59	14	
SC 62B	Diagnostic imaging equipment	70	9	
SC 62C	Equipment for radiotherapy, nuclear medicine and radiation dosimetry	38	5	
SC 62D	Electromedical equipment	96	33	

669

670

671

672 Click on the country for which you want the National Committee information.

Standards development > How we work > Technical Committees & Subcommittees > TC 62 > SC 62A Dashboard

SC 62A

Common aspects of electrical equipment used in medical practice

Scope Structure **Projects / Publications** Documents Votes Meetings Collaboration Tools

Membership Officers Liaisons Working Groups

Log in En Fr

Country	Country Code	P/O Status	IEC Membership
Australia	AU	P-Member	Full Member
Austria	AT	P-Member	Full Member
Belarus	BY	O-Member	Full Member
Belgium	BE	P-Member	Full Member
Brazil	BR	P-Member	Full Member
Bulgaria	BG	O-Member	Full Member
Canada	CA	P-Member	Full Member
China	CN	P-Member	Full Member

Facts and figures	
Secretariat	United States of America
Participating countries	26
Observer Countries	21


673
674

675 For example, if you selected Canada, the contact information will appear. There is a link
676 (circled) to e-mail the national committee.
677

Canada IEC Full Member

General **TC/SC Membership** TC/SC Secretariat Votes

Log in En Fr

IEC National Committee (NC)		Contact information	
	IEC National Committee of Canada Canadian National Committee of the IEC (CANCI/IEC) Standards Council of Canada 55 Metcalfe Street, Suite 600 Ottawa ON K1P 6L5 Canada	Telephone	
President	Mr Jacques Régis	Fax	
Secretary	Ms Lynne M Gibbens	Email	Send Email
		Website	scc.ca

Full contact details are available to authorized users after [log in](#).

678
679
680

681 **For an ISO committee**

682 Go to the ISO website at this link:

683 http://www.iso.org/iso/home/standards_development/list_of_iso_technical_committees.htm

684

685 At the bottom of the page is a list of Technical Committees (TCs).

List of ISO technical committees

Filter by technical sector:

All

Committee	Title	ISOTC working area	Standards published	Work programme
ISO/IEC JTC 1	Information technology	ISO/IEC JTC 1 home	2999	540
ISO/TC 1	Screw threads	ISO/TC 1 home	23	0
ISO/TC 2	Fasteners	ISO/TC 2 home	191	43
ISO/TC 4	Rolling bearings	ISO/TC 4 home	77	27

686

687

688 Scroll down and click on the TC you are interested in, for example TC 210

ISO/TC 209	Cleanrooms and associated controlled environments	ISO/TC 209 home	13	5
ISO/TC 210	Quality management and corresponding general aspects for medical devices	ISO/TC 210 home	25	13

689

690

691 At the bottom of the page you will find information on how many countries participate in that

692 TC. The number is a link. Click on it.

Total number of published ISO standards related to the TC and its SCs (number includes updates):	25
Number of published ISO standards under the direct responsibility of ISO/TC 210 (number includes updates):	25
Participating countries:	39
Observing countries:	17

693

694 Scroll down and click on the country for which you desire National Committee information (in

695 this example, Australia). The e-mail to contact will be available.

696

Australia (SA)

Membership: **Member body**

Standards Australia is recognised by the Commonwealth Government as the nation's peak Standards body. It is a not-for-profit, non-government organisation that coordinates standardization activities and facilitates the development of Australian Standards® by working with Government, industry and the community.

Through the Accreditation Board for Standards Development Organisations (ABSDO) other Standards Development Organisations can be accredited to develop Australian Standards. Additionally, excellence in design and innovation is promoted by Standards Australia through its Australian International Design Awards program.

Standards Australia meets national needs for contemporary, internationally aligned Standards and related services that deliver Net Benefit to Australia.

To support this objective, a Memorandum of Understanding (MoU) has existed between Standards Australia and the Commonwealth Government since 1988.

Standards Australia is also Australia's member of the International Organization for Standardization (ISO), the International Electrotechnical Commission (IEC) and the International Council of Societies of Industrial Design (ICSID), providing a direct link to the international arena and creating further standards development efficiencies.

Standards Australia is a company limited by guarantee, with 71 members representing groups interested in the development and application of standards and related products and services.

Standards Australia
Level 10, The Exchange Centre 20 Bridge Street
AU-Sydney NSW 2000

Postal Address:

GPO Box 476
AU-Sydney NSW 2001

Tel:

Fax:

E-mail: info@standards.org.au

Web: www.standards.org.au

Webstore: www.standards.org.au

697